Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

Novartis is also establishing a network of certified treatment centres throughout the country which will be fully trained on the use of Kymriah and appropriate patient care. Gilead in the picture ...

Bruno Strigini, chief executive of oncology at Novartis, said ... the drug, known as Kymriah, is the most expensive to go on sale. Strigini pointed out the price tag was below the amount ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Kymriah (tisagenlecleucel) is a prescription drug that’s used to treat certain types of leukemia and lymphoma. The drug is given as an intravenous (IV) infusion. Kymriah is usually given as a ...

CD19-directed autologous CAR T cell therapies such as Gilead's (NASDAQ:GILD) Yescarta and Tecartus, Bristol Myers' (BMY) Breyanzi, and Novartis (NYSE:NVS) (OTCPK:NVSEF) Kymriah are also included ...

Who Are the Key Players in the Kymriah Market? The Kymriah market is dominated by Novartis AG, a key player in CAR-T cell therapy innovation. Advancements in Kymriah and other CAR-T therapies have ...

"We're at the very beginning of what's going to be a big new field of medicine," said David Epstein, who helped license Kymriah from the University of Pennsylvania while at Novartis. Epstein left ...